CSIMarket


Esperion Therapeutics inc   (ESPR)
Other Ticker:  
 


 

Esperion Therapeutics inc

ESPR's Financial Statements and Analysis



Esperion Therapeutics inc narrowed forth quarter of 2023 net loss per share of $-0.36 compare to net loss per share of $-0.48 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.37 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.36 $  32 Mill
$+0.12     $+13M     +71.38 %



Esperion Therapeutics Inc 's Revenue rose by 71.38 % in forth quarter of 2023 (Dec 31 2023) year on year, to $32 million and declined by -5.06 % sequentially.


Esperion Therapeutics Inc is

More on ESPR's Income Statement



Esperion Therapeutics Inc 's in theforth quarter of 2023 recorded net loss of $-56.344 million, an increase from net loss of $-55.487 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on ESPR's Growth

Esperion Therapeutics Inc Inventories
Inventories grew by 86.42 % to $66 million from IV. Quarter a year ago, sequentially inventories rose by 27.58 %. In Dec 31 2023 company's net cash and cash equivalents decreased by $-33 million


Esperion Therapeutics inc does not pay out common stock dividend.

In trailing twelve-month period Esperion Therapeutics inc payed $ -1.31 cash per share, on a free-cash flow basis .


Tangible Book value fell to $ -4.41 per share from $ -3.67.

Company repurchased 8.79 million shares or 7.86 % in Dec 31 2023.


More on ESPR's Dividends

 Market Capitalization (Millions) 278
 Shares Outstanding (Millions) 103
 Total Debt (Millions $) 262
 Revenue (TTM) (Millions $) 116
 Net Income (TTM) (Millions $) -209
 Cash Flow (TTM) (Millions $) -43
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Esperion Therapeutics inc does not pay out common stock dividend.

In trailing twelve-month period Esperion Therapeutics inc had negative $ -1.31 cash flow per share, on a free-cash flow basis .


Tangible Book value fell to $ -4.41 per share from $ -3.67.

Company repurchased 8.79 million shares or 7.86 % in Dec 31 2023.


More on ESPR's Balance Sheets

 Market Capitalization (Millions) 278
 Shares Outstanding (Millions) 103
 Total Debt (Millions $) 262
 Revenue (TTM) (Millions $) 116
 Net Income (TTM) (Millions $) -209
 Cash Flow (TTM) (Millions $) -43
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Esperion Therapeutics inc Earnings

Esperion Therapeutics Inc Sees Revenue Growth and Reduction in Losses in Fiscal Q3 2023

As a financial journalist for the , I have been closely monitoring the recent financial results of Esperion Therapeutics Inc, a major player in the pharmaceutical industry. The company's fiscal three months ending December 31, 2023, showed a remarkable revenue growth of 71.378% to $32.25 million, leading to a decrease in losses to $-0.36 per share from $-0.48 in the previous year. Despite a slight decrease in revenue in the third quarter, the company managed to improve its earnings per share (EPS) from $-0.37 per share.
However, the fourth quarter of 2023 saw Esperion Therapeutics Inc facing a net shortfall of $-56.344 million, slightly higher than the previous year. The company also witnessed an increas...

Esperion Therapeutics Inc Achieves Remarkable Revenue Growth, Leading the Way in the Pharmaceutical Preparations Industry

Esperion Therapeutics Inc, a major player in the pharmaceutical preparations industry, has delivered outstanding financial results in its latest reporting period from July to September 2023. With an impressive revenue growth of 78.973% to reach $33.97 million, the company has significantly reduced its losses to just $-0.37 per share, compared to $-0.81 in the same period last year.
These remarkable figures position Esperion Therapeutics Inc as an industry leader, outperforming its peers in terms of top-line growth. While the rest of the Major Pharmaceutical Preparations industry reported a modest 1.86% increase in revenue during the same period, Esperion Therapeutics Inc has clearly surged ahead. This si...

Esperion Therapeutics Inc Reports Significant Financial Gains in Q2 2023, Outperforming Major Pharmaceutical Industry



Esperion Therapeutics Inc, a leading pharma...

Headline: Esperion Therapeutics Inc. Celebrates Strong Revenue Surge Amidst Challenging First Quarter of 2023 Earnings2.

Esperion Therapeutics Inc (ESPR) has recently announced a surge in revenue of 29.162% to $24.33 million from the comparable quarter a year before. This news is a promising indicator of growth for the company, despite a loss of $0.79 per share. While the deficit increased to $0.48 per share, revenue growth has continued to improve significantly from $18.82 million.
However, ESPR is not letting these financial losses bring them down. The company is proud of the dedication and hard work of their personnel, who continue to successfully handle adversity and catch up with global client demand while keeping net profitability. This positive attitude is key in ensuring that ESPR stays ahead of competitors and rem...


Date modified: 2024-02-27T17:31:35+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com